

# ACTA MEDICINAE KAZUISTIKY 2012

## Kompletní literatura

- 2 **První zkušenost s léčbou crizotinibem u nemocného s nemalobuněčným karcinomem plic s translokací EML4-ALK v České republice**  
prof. MUDr. Miloš Pešek, CSc. Klinika TRN FN Plzeň  
RNDr. Petr Grossmann Oddělení genetiky ŠPAÚ FN Plzeň
- 2 **Doxorubicin hydrochlorid v léčbě metastatického karcinomu prsu**  
MUDr. Igor Richter | MUDr. Jiří Bartoš, MBA Onkologické oddělení, Krajská nemocnice Liberec, a. s.  
doc. MUDr. Josef Dvořák, Ph.D. Klinika onkologie a radioterapie LF UK a FN Hradec Králové
- 3 **Příklad léčby axiální spondylartritidy infliximabem**  
MUDr. Markéta Fojtíková, Ph.D. Revmatologický ústav, Praha
- 3 **Depotní medroxyprogesteron acetát jako antikoncepce**  
MUDr. Stanislav Zeman Gynekologicko-porodnická ambulance, Velké Meziříčí
- 4 **Qutenza – novinka v topické léčbě bolesti**  
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny, Brno
- 4 **Neoadjuvantní cílená léčba karcinomu prsu**  
MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D.  
Onkologická klinika LF UP a FN Olomouc
- 4 **Karcinom prsu v těhotenství**  
MUDr. Katarína Petráková Klinika komplexní onkologické péče MOÚ, Brno

# První zkušenost s léčbou crizotinibem u nemocného s nemalobuněčným karcinomem plic s translokací EML4-ALK v České republice

prof. MUDr. Miloš Pešek, CSc. Klinika TRN FN Plzeň

RNDr. Petr Grossmann Oddělení genetiky ŠPAÚ FN Plzeň

- 1 Bowle, D. W. – Weickhardt, A. J. – Doebele, R. C. – Camidge, D. R. – Mámeno, A.: Crizotinib for the treatment of patients with advanced non-small cell lung cancer. *Drugs of Today*, 2012, 48 (4), s. 271–282.
- 2 Camidge, D. R. – Doebele, R. C.: Treating ALK-positive lung cancer—early successes and future challenges. *Nat Rev Clin Oncol*, 2012, 9, s. 268–277.
- 3 Camidge, D. R. – Kono, S. A. – Lu, X., et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. *J Thorac Oncol*, 2011, 6 (4), s. 774–780.
- 4 Pešek, M. – Grossmann, P. – Mukenšabl, P. – Minárik, M.: První zkušenosti s vyšetřováním zlomu genu ALK (anaplastické lymfomové kinázy) a s podáním crizotinibu u vybraných nemocných s nemalobuněčnými karcinomy plic (NSCLC). *Studia Pneumologica Phthiseol*, 2012, 72 (3), s. 159–162.
- 5 Ryška, A. – Petruželka, L. – Skříčková, J. – Kolek, V. – Hajduch, M. – Matěj, R. – Uvirová, M. – Pešek, M. – Dvořáčková, J. – Horyňchová, H.: Interdisciplinární konsenzus pro prediktivní vyšetřování u nemalobuněčného karcinomu plic (NSCLC) – aktualizace 2012. *Studia Pneumologica Phthiseol*, 2012, 72, 3, s. 168.
- 6 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 7 Yang, J. – Zhang, X. – Su, J. – Chen, H. – Tian, H. – Juany, Y. – Xu, C. – Wu, Y. L.: Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. *Journal of Clin Oncol*, 2011, ASCO Annual Meeting Proceedings (post-Meeting Edition), 29 (15) dopl., 2011, abstrakt 10517.
- 8 Zhang, X. – Zhang, S. – Yang, X., et al.: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. *Mol Cancer*, 2010, 9, s. 188.
- 9 Lee, J. K. – Park, H. S. – Kim, D.-W. – Kulig, K. – Kim, T. M. – Lee, S.-H. – Jeon, Y.-K. – Chung, D. H. – Heo, D. S. – Kim, W.-H. – Bang, Y.-J.: Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild type advanced non small cell lung cancer. *Cancer*, 2012, 118 (14), s. 3579–3586.

## Doxorubicin hydrochlorid v léčbě metastatického karcinomu prsu

MUDr. Igor Richter | MUDr. Jiří Bartoš, MBA Onkologické oddělení, Krajská nemocnice Liberec, a. s.  
doc. MUDr. Josef Dvořák, Ph.D. Klinika onkologie a radioterapie LF UK a FN Hradec Králové

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [on-line]. Masarykova univerzita, 2005, cit. 20. 11. 2011. Dostupný z: <http://www.svod.cz>. Verze 7.0 [2007].
- 2 Neidhart, J. A. – Gochnour, D. – Roach, R., et al.: A comparison of mitoxantrone and doxorubicin in breast cancer. *J Clin Oncol*, 1986, 4, s. 672.
- 3 Hortobagyi, G. N. – Yap, H. Y. – Kau, S. W., et al.: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. *Am J Clin Oncol*, 1989, 12, s. 57.
- 4 Henderson, I. C. – Allegra, J. C. – Woodcock, T., et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. *J Clin Oncol*, 1989, 7, s. 560.
- 5 Sledge, G. W. – Neuberg, D. – Bernardo, P., et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). *J Clin Oncol*, 2003, 21, s. 588.
- 6 Norris, B. – Pritchard, K. I. – James, K., et al.: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group study MA8. *J Clin Oncol*, 2000, 18, s. 2385.
- 7 Blomqvist, C. – Elomaa, I. – Rissanen, P., et al.: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. *J Clin Oncol*, 1993, 11, s. 467.
- 8 Geyer, C. E. Jr. – Green, S. J. – Moinpour, C. M., et al.: Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. *Breast Cancer Res Treat*, 1998, 51, s. 169.
- 9 Piccart, M. J. – Burzykowski, T., et al.: Taxanes alone or in combination with antracyclines as first-line therapy for patients with metastatic breast cancer. *J Clin Oncol*, 2008, 28, s. 1980–1986.
- 10 Gianni, L. – Munzone, E. – Capri, G., et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. *J Clin Oncol*, 1995, 13, s. 2688.
- 11 Lluch, A. – Ojeda, B. – Colomer, R., et al.: Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy. *Cancer*, 2000, 89, s. 2169.
- 12 Giordano, S. H. – Booser, D. J. – Murray, J. L., et al.: A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. *Clin Cancer Res*, 2002, 8, s. 3360.
- 13 Bria, E. – Giannarelli, D. – Felici, A., et al.: Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. *Cancer*, 2005, 103, s. 672.
- 14 Biganzoli, L. – Cufer, T. – Bruning, P., et al.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. *J Clin Oncol*, 2002, 20, s. 3114.
- 15 Langley, R. E. – Carmichael, J. – Jones, A. L., et al.: Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus

cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J Clin Oncol*, 2005, 23, s. 8322.

- 16 **Jassem, J. – Pienkowski, T. – Pluzanska, A., et al.:** Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. *J Clin Oncol*, 2001, 19, s. 1707.
- 17 **Nabholtz, J. M. – Falkson, C. – Campos, D., et al.:** Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. *J Clin Oncol*, 2003, 21, s. 968.
- 18 **Bontenbal, M. – Creemers, G. J. – Braun, H. J., et al.:** Phase II to III

study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a dutch community setting trial for the Clinical Trial Group of the Comprehensive Cancer Centre. *J Clin Oncol*, 2005, 23, s. 7081.

- 19 **Alba, E. – Martin, M. – Ramos, M., et al.:** Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. *J Clin Oncol*, 2004, 22, s. 2587.
- 20 **Gennari, A. – Formani, M. P. – Pronzito, P.:** Her2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. *J Natl Cancer Inst*, 2008, 100, s. 14–20.

## Příklad léčby axiální spondylartritidy infliximabem

MUDr. Markéta Fojtíková, Ph.D. Revmatologický ústav, Praha

- 1 **Seper, J., et al.:** The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis*, 2009, 68, s. ii1–44.
- 2 **Rudwaleit, M., et al.:** The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- 3 **Aydin, S. Z., et al.:** Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. *Ann Rheum Dis*, 2012, 71, s. 56–60.
- 4 **Baralioakos, X., et al.:** Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. *Rheumatology* (Oxford), 2012, 51, s. 1378–1387.
- 5 **Pavelka, K.:** Doporučení české revmatologické společnosti pro léčbu ankylozující spondylitidy. *Čes Revmatol*, 2012, 1, s. 4–11.
- 6 **Pedersen, S. J., et al.:** ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF $\alpha$  inhibitors. *Ann Rheum Dis*, 2011, 70, s. 1375–1381.
- 7 **Dougados, M., et al.:** ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Ann Rheum Dis*, 2011, 70, s. 51.

## Depotní medroxyprogesteron acetát jako antikoncepce

MUDr. Stanislav Zeman Gynekologicko-porodnická ambulance, Velké Meziříčí

- 1 **Čepický, P. – Libalová, Z.:** Gestagení antikoncepce. *Moderní babičtví*, 2008, 15, s. 1–3.
- 2 **Jain, J. – Jakimiuk, A. J. – Bode, F. R., et al.:** Contraceptive efficacy and safety of DMPA-SC. *Contraception*, 2004, 70, s. 269–275.
- 3 **Kaunitz, A. M.:** Long-acting injectable contraception with depot medroxyprogesterone acetate. *Am J Obstet Gynecol*, 1994, 170 (5Pt2), s. 1543–1549.
- 4 **Petta, C. A. – Faundes, A. – Dunson, T. R., et al.:** Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. *Fertil Steril*, 1998, 69, s. 252–257.
- 5 **Polez, L. M. – Neumann, S. J. – Grimas, D. A., et al.:** Immediate start of hormonal contraceptives for contraception. *Cochrane Database Syst Rev*, 2008, 2, CD006260.
- 6 **Belsey, E. M.:** Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation. *Adv Contracept*, 1991, 7, s. 257–270.
- 7 **Čepický, P.:** Hormonální antikoncepce. *Remedia*, 2004, 14, s. 259–266, dostupné z: [www.remmedia.cz/Archiv-rocniku/Rocnik-2004/3-2004/Hormonalni-antikoncepce](http://www.remmedia.cz/Archiv-rocniku/Rocnik-2004/3-2004/Hormonalni-antikoncepce).
- 8 **Thomas, D. B. – Ray, R. M.:** The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. 29. *Int J Cancer*, 1991, 49, s. 186–190.
- 9 **Mattson, R. H. – Frajer, J. A. – Caldwell, B. V. – Siconolfi, B. C.:** Treatment of seizures with medroxyprogesterone acetate: preliminary report. *Neurology*, 1984, 34, s. 1255–1258.
- 10 **Frederiksen, M. C.:** Depot medroxyprogesterone acetate contraception in women with medical problems. *J Reprod Med*, 1996, 41, s. 414–418.
- 11 **De Ceulaer, K. – Gruber, C. – Gates, R. – Serjeant, G. R.:** Medroxyprogesterone acetate and homozygous sickle-cell disease. *Lancet*, 1982, 2, s. 229–231.
- 12 **Harel, Z. – Johnson, C. C. – Gold, M. A., et al.:** Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. *Contraception*, 2010, 81, s. 281–291.
- 13 **Harel, Z. – Wolter, K., – Gold, A. M., et al.:** Biopsychosocial variables associated with substantial Bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%. *Contraception*, 2010, 82, s. 503–512.
- 14 **US Food and Drug Administration:** Black box warning added concerning long-term use of Depo-Provera. *Contraceptive Injection*, 2004.
- 15 **World Health Organization:** Department of Reproductive Health and Research. WHO statement on hormonal contraception and bone health. *Wkly Epidemiol Rec*, 2005, 80, s. 302–304.
- 16 **The National Collaborating Centre for Women's and Children's Health:** Long-acting reversible contraception—Clinical Guideline 30. London, United Kingdom: *National Institute for Health and Clinical Excellence*, 2005, s. 1–176.
- 17 **Cromer, A. C. – Scholes, D. – Berenson, A., et al.:** Depot medroxyprogesterone acetate and bone mineral density in adolescents- the black box warning: A position paper of the Society for Adolescent Medicine.

*J Adol Health*, 2006, 39, s. 296–301.

- 18 **Black, A.**: Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus—update on depot medroxyprogesterone acetate (DMPA). *J Obstet Gynaecol Can*, 2006, 28, s. 305–313.
- 19 **American College of Obstetricians and Gynecologists**: ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects. *Obstet Gynecol*, 2008, 112, s. 727–730.
- 20 **Guilbert, E. R. – Brown, J. P. – Kaunitz, A. M., et al.**: The use of depot medroxyprogesterone acetate in contraception and its potential impact on skeletal health. *Contraception*, 2009, 79, s. 167–177.
- 21 **Tang, O. S. – Tang, G. – Yip, P., et al.**: Long-term depot medroxyprogesterone acetate and bone mineral density. *Contraception*, 1999, 59, s. 25–29.

## Qutenza – novinka v topické léčbě bolesti

MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny, Brno

- 1 **Attal, N. – Cruccu, G. – Baron, R. – Haanpaa, M. – Hanson, P. – Jensen, T. – Numikko, T.**: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. *European Journal of Neurology*, 2009, 8, s. 1010–1018.
- 2 **Backonja, M. – Wallace, M. – Blonsky, R. – Cutler, B. – Malan, P. – Rauck, R. – Tobiáš, J.**: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. *Lancet Neurol*, 2008, 7, s. 1106–1112.
- 3 **Simpson, D. – Brown, S. – Tobiáš, J.**: Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. *Neurology*, 2008, 70, s. 2305–2313.

## Neoadjuvantní cílená léčba karcinomu prsu

MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D.

Onkologická klinika LF UP a FN Olomouc

- 1 **Gianni, L. – Eiermann, W. – Semiglazov, V. – Manikhas, A. – Lluch, A. – Toulandin, S. – Zambetti, M. – Vazquez, F. – Byakhov, M. – Lichinitser, M. – Kliment, M. A. – Ciruelos, E. – Jeda, B. – Mansutti, M. – Bozhok, A. – Baronio, R. – Feyereislova, A. – Barton, C. – Valagussa, P. – Baselga, J.**: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet*, 2010, 30, 375 (9712), s. 377–384.
- 2 **Untch, M. – Loibl, S. – Bischoff, J. – Eidtmann, H. – Kaufmann, M. – Blohmer, J. U. – Hilfrich, J. – Strumberg, D. – Fasching, P. A. – Kreienberg, R. – Tesech, H. – Hanusich, C. – Gerber, B. – Rezai, M. – Jackisch, C. – Hober, J. – Kühn, T. – Nekludova, V. – von Minckwitz, G. – German Breast Group (GBG) – Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group**: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol*, 2012, 13 (2), s. 135–144.
- 3 **Baselga, J. – Bradbury, I. – Eidtmann, H. – Di Vosino, S. – de Azambuja, E. – Aura, C. – Gómez, H. – Dinh, P. – Gaudia, K. – Van Dooren, V. – Aktan, G. – Goldhirsch, A. – Chány, T. W. – Horváth, Z. – Coccia-Portugal, M. – Domont, J. – Tseng, L. M. – Kunz, G. – Sohn, J. H. – Semiglazov, V. – Lermo, G. – Palacova, M. – Probachai, V. – Pusztai, L. – Untch, M. – Gerber, R. D. – Piccart-Gebhart, M. – NeoALTTO Study Team**: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2012, 379 (9816), s. 633–640.
- 4 **Gianni, L. – Pienkowski, T. – Im, Y. H. – Roman, L. – Tseng, L. M. – Liu, M. C. – Lluch, A. – Staroslawska, E. – de la Haba-Rodriguez, J. – Im, S. A. – Pedrini, J. L. – Poirier, B. – Morandi, P. – Semiglazov, V. – Srimuninnimit, V. – Bianchi, G. – Szado, T. – Ratnayake, J. – Ross, G. – Valagussa, P.**: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13 (1), s. 25–32.
- 5 **Abstract 1BA**: Subcutaneous administration of trastuzumab in patients with HER2-positive early breast cancer: Results from the Phase III randomized, open-label, multi-center (neo)adjuvant HannaH study. *Congress Alerts, Clinical Spotlight on HER2-Positive Early Breast Cancer from the 2012 European Breast Cancer Conference in Vienna*. [www.primeoncology.org/online\\_education/solid\\_tumor/2012/cspbrest2012\\_vienna.aspx](http://www.primeoncology.org/online_education/solid_tumor/2012/cspbrest2012_vienna.aspx).
- 6 **Dawood, S. – Broglio, K. – Buzdar, A. U. – Hortobagyi, G. N. – Giordano, S. H.**: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. *J Clin Oncol*, 2010, 28 (1), s. 92–98.
- 7 **Guarneri, V. – Barbieri, E. – Dieci, M. V. – Piacentini, F. – Conte, P.**: Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. *Cancer Treat Rev*, 2010, 36, dopl. 3, s. S62–6. Review.

## Karcinom prsu v těhotenství

MUDr. Katarína Petráková Klinika komplexní onkologické péče MOÚ, Brno

- 1 **Lambe, M. – Hsieh, C. C. – Trichopoulos, D., et al.**: Transient increase in the risk of breast cancer after giving birth. *N Engl J Med*, 1994, 331, s. 5–9.
- 2 **Beadle, B. M. – Middleton, L. P. – Tereffe, W., et al.**: The impact of pregnancy on breast cancer outcomes in women < or = 35 years. *Cancer*, 2009, 115 (6), s. 1174–1184.
- 3 **Mathelin, C. – Annane, K. – Treisser, A., et al.**: Pregnancy and post-partum breast cancer: a prospective study. *Anticancer Res*, 2008, 28 (4c), s. 2447–2452.
- 4 **Giacalone, P. L. – Laffargue, F. – Benos, P., et al.**: Chemotherapy for breast carcinoma during pregnancy: A French national survey. *Cancer*, 1999, 86, s. 2266–2272.
- 5 **Berry, D. L. – Theriault, R. L. – Holme, F. A., et al.**: Management of breast cancer during pregnancy using a standardized protocol. *J Clin Oncol*, 1999, 17, s. 855–861.